Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD Ingestion for Muscle Injury Recovery
NCT04586712Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Countries
- 1
- Sponsor
- University of Florida
- Modality
- Small Molecules
- Drugs
- cannabidiol
- Conditions
- muscle injury
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in muscle injury (2 arms), sponsored by University of Florida. Primary endpoints: Self-report Ratings of Muscle Soreness at Day 12 and Self-report Ratings of Disability at Day 12. Started Mar 2021; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Active CBD-extract
Active Dose (2000mg/30mL hemp extract = 67.5mg/day)
Vehicle-Control (Placebo)
(0mg/30mL hemp extract = no hemp extract)
03
Who it enrols
Healthy adults aged 18-35, excluding those with regular use of cannabis, tobacco, certain prescription medications, or dietary supplements, and those with a history of seizure, head trauma, liver, renal, or cardiovascular disease.
04
Endpoints
Primary
Self-report Ratings of Muscle Soreness
Self-report Ratings of Disability
Secondary
Pain Anxiety Symptom Scale - 20
Pain Catastrophizing Scale
Fear of Pain Questionnaire
Maximal Voluntary Isometric Contraction
Beyond the preview
Go deeper on NCT04586712.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586712.